The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Single-agent lenalidomide for newly diagnosed myeloma with on-demand dexamethasone: A phase II trial.
F. Buadi
No relevant relationships to disclose
M. Lacy
Research Funding - Celgene
A. Dispenzieri
Honoraria - Binding Site
Research Funding - Celgene
B. LaPlant
No relevant relationships to disclose
K. M. Laumann
No relevant relationships to disclose
G. S. Nowakowski
No relevant relationships to disclose
S. R. Hayman
No relevant relationships to disclose
K. Detweiler Short
No relevant relationships to disclose
D. Dingli
No relevant relationships to disclose
M. A. Gertz
Honoraria - Celgene; Millennium
P. R. Greipp
No relevant relationships to disclose
J. A. Lust
No relevant relationships to disclose
T. E. Witzig
No relevant relationships to disclose
S. R. Zeldenrust
No relevant relationships to disclose
S. J. Russell
No relevant relationships to disclose
V. Rajkumar
No relevant relationships to disclose
S. Kumar
Consultant or Advisory Role - Merck
Research Funding - Celgene; Cephalon; Genzyme; Millennium; Novartis